KospicyKorean filings in English
Filings / GeneBioTechCo.,Ltd.

Material Event Report — Share Buyback Decision

GeneBioTechCo.,Ltd. · 주요사항보고서(자기주식취득결정)

8-KKOSDAQ · 086060 Filed 2026-11-16Korean original on DART

English form view 60% translated

Translated from a fixed dictionaryLeft in Korean (free text, names)Numbers and dates are copied unchanged

Material Event Report (Treasury Stock Acquisition Decision)

6.3

(주)진바이오텍

Material Event Report / KRX Mandatory Disclosure

To: Financial Services Commission / Korea Exchange2026-11-16
Company Name:(주)진바이오텍
CEO:이 찬 호
Head Office Address:충남 공주시 계룡면 신원사로 166
(Tel) 041-853-9961
(홈페이지)http://www.genebiotech.co.kr
Preparer:(Title) Director(성 명) 김기태
(Tel) 02-6300-8222

Decision on treasury stock acquisition

1. Shares to Be Acquired (shares)Common Shares86,000
Other Shares-
2. Planned Acquisition Amount (KRW)Common Shares434,300,000
Other Shares-
3. Expected Acquisition PeriodStart Date2026-11-17
End Date2027-02-16
4. Expected Holding PeriodStart Date-
End Date-
5. Purpose of Acquisition임직원 성과보상 및 주가안정
6. Acquisition Method코스닥시장을 통한 장내 직접취득
7. Entrusted Investment BrokerNH투자증권(NH Investment & Securities Co., Ltd)
8. Treasury Shares Held Before AcquisitionAcquisition within distributable profits (shares)Common Shares-Ratio (%)-
Other Shares-Ratio (%)-
Other Acquisitions (shares)Common Shares-Ratio (%)-
Other Shares-Ratio (%)-
9. Acquisition Resolution Date2026-11-16
- Independent (Outside) Directors* PresentPresent (persons)1
Absent (persons)-
- Auditor (audit committee member not an independent (outside) director*) attendancePresent
10. Daily Purchase Order Limit (1 days)Common Shares8,600
Other Shares-

* Independent directors for listed companies; outside directors for unlisted companies

11. Other Matters Relevant to Investment Decisions

- 상기 '1.취득예정주식(주)'은 이사회 결의일 직전 거래일 한국거래소 종가를 기준으로 하여 산정하였습니다.(2026-11-13, 5,050원)- 당사는 상기 '2. 취득예정금액(원)'에 기재한 금액을 기준으로 자기주식을 취득할 예정이며, 향후 주가 변동에 따라 실제 취득주식수량 및 취득금액은 변동될 수 있습니다.- 상기 '4. 보유예상기간'은 회사의 재무상태, 시장환경 변화. 경영환경 등을 고려하여 결정할 예정입니다.- 상기 '5. 취득목적'과 관련하여 당사는 2026-11-16 이사회 결의에 따라 임직원 성과보상 및 주가안정에 사용할 목적으로 자기주식을 취득하는 것입니다. 취득한 자기주식의 처분에 관한 사항은 향후 임직원 성과보상 등 경영 환경에 따라 결정할 예정입니다.- 상기 10. 1일 매수 주문수량 한도는 아래의 산출 근거에 따라 계산되었습니다.※ [(1)과 (2) 중 많은 수량]과 (3) 중 적은 수량 (1) 취득신고주식수의 10% : 8,600주 (2) 이사회결의일 전일로부터 1개월간 일평균거래량의 25% : 3,788주 (3) 발행주식 총수의 1% : 86,105주

【Treasury Share Acquisition Limit】
ItemAmount
1. Distributable Profit Limit under the Commercial Act as of Prior Fiscal Year-Enda. Net Assets39,612,500,162
b. Share Capital4,305,293,500
C. Sum of Capital Reserve and Legal Reserve Accumulated through Prior Fiscal Year13,924,385,689
D. Unrealized Gains Prescribed by Presidential Decree310,598,711
Subtotal (A-B-C-D)21,072,222,262
2. Treasury Share Acquisition Amount Since Prior Fiscal Year-End-
3. Dividends Resolved at the AGM Since Prior Fiscal Year-End and Related Legal Reserve473,582,285
4. Quarterly/Interim Dividends Resolved by the Board Since Prior Fiscal Year-End and Related Legal Reserve284,149,371
5. Trust Contract Amount-
6. Acquisition Cost of Treasury Shares Disposed Since Prior Fiscal Year-End (Moving Average Method)-
Treasury share acquisition limit (1-2-3-4-5+6)20,314,490,606
【Treasury Shares Held Before Acquisition Resolution】
(Unit: shares)
Acquisition methodType of SharesBeginning quantityChange in quantityEnding quantityRemarks
Acquired (+)Disposed (-)Retired (-)
Acquisition within distributable profitsDirect acquisitionDirect On-Market AcquisitionCommon Shares------
Other Shares------
Direct OTC acquisitionCommon Shares------
Other Shares------
Tender offerCommon Shares------
Other Shares------
Subtotal (a)Common Shares------
Other Shares------
Acquisition under trust agreementShares held by trusteeCommon Shares------
Other Shares------
Shares held in kindCommon Shares------
Other Shares------
Subtotal (b)Common Shares------
Other Shares------
Other acquisitions (c)Common Shares------
Other Shares------
Total (a+b+c)Common Shares------
Other Shares------